New longer term Phase I/IIa data for the hRPC therapy programme in Retinitis Pigmentosa (RP) is encouraging, showing a sustained improvement in visual acuity in patients up to 12 months. We make the point that a 12 month 14.3 letter improvement vs baseline and 7.3 letter improvement vs. untreated eye is clinical meaningful within this patient population, although their baseline measurements and severity of patients at time of treatment remains publically unknown. Positively, the long-term dat
24 Feb 2020
Long term data in retinitis Pigmentosa shows sustained improvements
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Long term data in retinitis Pigmentosa shows sustained improvements
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
24 Feb 2020 -
Author:
Edward Thomason -
Pages:
4
New longer term Phase I/IIa data for the hRPC therapy programme in Retinitis Pigmentosa (RP) is encouraging, showing a sustained improvement in visual acuity in patients up to 12 months. We make the point that a 12 month 14.3 letter improvement vs baseline and 7.3 letter improvement vs. untreated eye is clinical meaningful within this patient population, although their baseline measurements and severity of patients at time of treatment remains publically unknown. Positively, the long-term dat